Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
182
Views
29
CrossRef citations to date
0
Altmetric
Original Research

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Valentina Burgio1 Department of Medical Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, ItalyORCID Iconhttps://orcid.org/0000-0002-0146-4136
ORCID Icon,
Massimo Iavarone2 Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy
,
Giovanni Giuseppe Di Costanzo3 Department of Hepatology, Naples, 80131, Italy
,
Fabio Marra4 Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Firenze, Italy
,
Sara Lonardi5 Early Phase Clinical Trial Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy;6 Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, ItalyORCID Iconhttps://orcid.org/0000-0002-7593-8138
ORCID Icon,
Emiliano Tamburini7 Department of Oncology and Palliative Care, Cardinale Hospital, Naples, ItalyORCID Iconhttps://orcid.org/0000-0003-4619-7091
ORCID Icon,
Fabio Piscaglia8 Division of Internal Medicine, Hepatobiliary and Immunoallergic Disease, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0001-8264-1845
ORCID Icon,
Gianluca Masi9 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy;10 Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
,
Ciro Celsa11 Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.), University of Palermo, Palermo, 90127, Italy
,
Francesco Giuseppe Foschi12 Internal Medicine, Infermi Hospital, Faenza (AUSL ROMAGNA), Ravenna, Italy
,
Marianna Silletta13 Department of Oncology, Campus Bio Medico, Roma, Italy
,
Daniela Caterina Amoruso14 Hepatology Unit, Internal Medicine, Area Stabiese Hospital, Naples, Italy
,
Margherita Rimini15 Department of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, Modena, 4121, Italy
,
Mariangela Bruccoleri2 Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, ItalyORCID Iconhttps://orcid.org/0000-0001-7400-4854
ORCID Icon,
Raffaella Tortora3 Department of Hepatology, Naples, 80131, Italy
,
Claudia Campani4 Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Firenze, ItalyORCID Iconhttps://orcid.org/0000-0003-3842-782X
ORCID Icon,
Caterina Soldà6 Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
,
Massimo Giuseppe Viola16 Department of General Surgery and Emergency Surgery, Cardinale Hospital, Tricase, Italy
,
Antonella Forgione8 Division of Internal Medicine, Hepatobiliary and Immunoallergic Disease, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
,
Fabio Conti12 Internal Medicine, Infermi Hospital, Faenza (AUSL ROMAGNA), Ravenna, Italy
,
Francesca Salani9 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy;10 Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
,
Silvia Catanese9 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy;10 Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
,
Carmelo Marco Giacchetto17 Section of Gastroenterology & Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, 90127, Italy
,
Claudia Fulgenzi13 Department of Oncology, Campus Bio Medico, Roma, Italy
,
Carmine Coppola14 Hepatology Unit, Internal Medicine, Area Stabiese Hospital, Naples, Italy
,
Pietro Lampertico18 Liver Center, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy
,
Antonio Pellino6 Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy;19 Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
,
Gabriele Rancatore17 Section of Gastroenterology & Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, 90127, ItalyORCID Iconhttps://orcid.org/0000-0001-9261-2087
ORCID Icon,
Giuseppe Cabibbo17 Section of Gastroenterology & Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, 90127, Italy
,
Francesca Ratti20 Hepatobiliary Surgery Division, Liver Center, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy
,
Federica Pedica21 Department of Experimental Oncology, Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy
,
Angelo Della Corte22 Department of Radiology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy
,
Massimo Colombo18 Liver Center, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy
,
Francesco De Cobelli23 School of Medicine, Vita-Salute San Raffaele University, Milan, 20132, Italy
,
Luca Aldrighetti20 Hepatobiliary Surgery Division, Liver Center, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy
,
Stefano Cascinu1 Department of Medical Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy;23 School of Medicine, Vita-Salute San Raffaele University, Milan, 20132, Italy
&
Andrea Casadei-Gardini1 Department of Medical Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy;23 School of Medicine, Vita-Salute San Raffaele University, Milan, 20132, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6289-7202
ORCID Icon show all
Pages 9379-9389 | Published online: 24 Dec 2021

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Kun-Ming Chan, Yin Lai, Hao-Chien Hung, Jin-Chiao Lee, Chih-Hsien Cheng, Yu-Chao Wang, Tsung-Han Wu, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Ching-Ting Wang, Pei-Mei Chai, Hsin-Yi Lien & Wei-Chen Lee. (2023) Significance of Physical Status and Liver Function Reserve for Outcome of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib Treatment. Journal of Hepatocellular Carcinoma 10, pages 281-290.
Read now
Bernardo Stefanini, Luca Ielasi, Rusi Chen, Chiara Abbati, Matteo Tonnini, Francesco Tovoli & Alessandro Granito. (2023) TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy 23:3, pages 279-291.
Read now
Mara Persano, Andrea Casadei-Gardini, Valentina Burgio, Mario Scartozzi, Stefano Cascinu & Margherita Rimini. (2023) Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?. Expert Review of Anticancer Therapy 23:1, pages 19-27.
Read now
Margherita Rimini, Nicole Liscia, Valentina Burgio & Andrea Casadei-Gardini. (2022) Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development. Expert Opinion on Investigational Drugs 31:5, pages 483-494.
Read now

Articles from other publishers (25)

Giuseppe Cabibbo, Bruno Daniele, Mauro Borzio, Andrea Casadei-Gardini, Umberto Cillo, Agostino Colli, Massimiliano Conforti, Vincenzo Dadduzio, Francesco Dionisi, Fabio Farinati, Ivan Gardini, Edoardo Giovanni Giannini, Rita Golfieri, Maria Guido, Andrea Mega, Michela Cinquini, Fabio Piscaglia, Lorenza Rimassa, Laura Romanini, Anna Pecorelli, Rodolfo Sacco, Marta Scorsetti, Luca Viganò, Alessandro Vitale & Franco Trevisani. (2024) Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments. Digestive and Liver Disease 56:3, pages 394-405.
Crossref
Rafał Becht, Kajetan Kiełbowski & Michał P. Wasilewicz. (2024) New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow. International Journal of Molecular Sciences 25:3, pages 1456.
Crossref
Xuefeng Hua, Ziwei Yin, Jin Liang, Wenbin Chen & Hui Gong. (2024) Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study. European Journal of Gastroenterology & Hepatology 36:1, pages 120-128.
Crossref
Silvia Camera, Margherita Rimini, Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Francesca Salani, Mariarosaria Marseglia, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Sara Lonardi, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Silvia Foti, Fabio Piscaglia, Mario Scartozzi, Stefano Cascinu & Andrea Casadei-Gardini. (2024) Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma. Targeted Oncology 19:1, pages 29-39.
Crossref
Vikash Jaiswal, Maha Hameed, Sidra Naz, Poulami Roy, Novonil Deb, Janta Ukrani, Gautham Varun Krishna Mohan, Amira M Taha, Helen Huang, Vikash Kumar, Bhavyakumar Vachhani, Abdelrahman M Attia, Supti D Nath, Mostafa A Solimn & Dattatreya Mukherjee. (2023) Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis . JGH Open 7:12, pages 832-840.
Crossref
Landon L. Chan & Stephen L. Chan. (2023) The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment. Clinical and Molecular Hepatology 29:4, pages 909-923.
Crossref
Shuai Wang, Rui Wang, Nan Xu, Xuyong Wei, Yijie Yang, Zhengxing Lian, Beini Cen, Chenchen Shen, Wangyao Li, Jianguo Wang, Zhensheng Zhang, Linsong Tang, Qiang Wei, Di Lu & Xiao Xu. (2023) SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment. Hepatology 78:4, pages 1064-1078.
Crossref
Najib Ben Khaled, Bernhard Mörtl, Dominik Beier, Florian P. Reiter, Dorota Pawlowska-Phelan, Andreas Teufel, Daniel Rössler, Daniel F. Schwade, Alexander Philipp, Ilja Kubisch, Ursula Ehmer, Andreas Geier, Christian M. Lange, Julia Mayerle, Karin Berger, Enrico N. De Toni & Stefan Munker. (2023) Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study. European Journal of Cancer 192, pages 113248.
Crossref
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Takashi Niizeki, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Bernardo Stefanini, Atsushi Hiraoka, Takuya Sho, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Claudia Campani, Elisabeth Amadeo, Federico Rossari, Valentina Burgio, Stefano Cascinu, Mario Scartozzi & Andrea Casadei-Gardini. (2023) Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. European Journal of Cancer 189, pages 112933.
Crossref
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Francesca Salani, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Marta Schirripa, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mario Scartozzi, Stefano Cascinu & Andrea Casadei-Gardini. (2023) Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. Journal of Cancer Research and Clinical Oncology 149:10, pages 7565-7577.
Crossref
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu & Andrea Casadei-Gardini. (2022) Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. Journal of Cancer Research and Clinical Oncology 149:9, pages 5591-5602.
Crossref
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Lorenza Rimassa, Mario Scartozzi, Stefano Cascinu & Andrea Casadei-Gardini. (2023) Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?. Targeted Oncology 18:2, pages 221-233.
Crossref
Simon Gray, Angela Lamarca, Mairéad G. McNamara, Julien Edeline, Karen Piper‐Hanley, Juan W. Valle & Richard A. Hubner. (2022) Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma. Liver Cancer International 4:1, pages 13-27.
Crossref
Andrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu & Alessandro Cucchetti. (2023) Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. European Journal of Cancer 180, pages 9-20.
Crossref
Rodolfo Sacco, Daryl Ramai, Raffaella Tortora, Giovan Giuseppe di Costanzo, Michela Emma Burlone, Mario Pirisi, Piera Federico, Bruno Daniele, Marianna Silletta, Paolo Gallo, Caterina Cocuzza, Maurizio Russello, Giuseppe Cabibbo, Gabriele Rancatore, Silvia Cesario, Gianluca Masi, Luca Marzi, Andrea Mega, Alessandro Granito, Giulia Pieri, Edoardo G. Giannini, Rosa Paolillo, Gennaro Gadaleta-Caldarola, Vincenzo Dadduzio, Guido Giordano, Luca Giacomelli, Simonetta Papa, Matteo Renzulli, Marcello Maida, Michele Ghidini, Mauro Borzio & Antonio Facciorusso. (2023) Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis. Cancers 15:2, pages 381.
Crossref
Jia Luo, Benjian Gao, Zhiyu Lin, Hua Fan, Wen Ma, Danfei Yu, Qian Yang, Jing Tian, Xiaoli Yang & Bo Li. (2022) Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis. Frontiers in Oncology 12.
Crossref
Margherita Rimini, Wonseok Kang, Valentina Burgio, Mara Persano, Tamoko Aoki, Shigeo Shimose, Toshifumi Tada, Takashi Kumada, Takuya Sho, Eleonora Lai, Ciro Celsa, Claudia Campani, Matteo Tonnini, Emiliano Tamburini, Atsushi Hiraoka, Koichi Takaguchi, Naoshi Nishida, Hideki Iwamoto, Ei Itobayashi, Kunihiko Tsuji, Naoya Sakamoto, Toru Ishikawa, Hidenori Toyoda, Masatoshi Kudo, Takumi Kawaguchi, Takeshi Hatanaka, Kazugiro Nouso, Goki Suda, Giuseppe Cabibbo, Fabio Marra, Angelo Della Corte, Francesca Ratti, Federica Pedica, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu & Andrea Casadei‐Gardini. (2022) Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib. Hepatology Research 52:12, pages 1050-1059.
Crossref
M. Rimini, L. Rimassa, K. Ueshima, V. Burgio, S. Shigeo, T. Tada, G. Suda, C. Yoo, J. Cheon, D.J. Pinato, S. Lonardi, M. Scartozzi, M. Iavarone, G.G. Di Costanzo, F. Marra, C. Soldà, E. Tamburini, F. Piscaglia, G. Masi, G. Cabibbo, F.G. Foschi, M. Silletta, T. Pressiani, N. Nishida, H. Iwamoto, N. Sakamoto, B.-Y. Ryoo, H.J. Chon, F. Claudia, T. Niizeki, T. Sho, B. Kang, A. D’Alessio, T. Kumada, A. Hiraoka, M. Hirooka, K. Kariyama, J. Tani, M. Atsukawa, K. Takaguchi, E. Itobayashi, S. Fukunishi, K. Tsuji, T. Ishikawa, K. Tajiri, H. Ochi, S. Yasuda, H. Toyoda, C. Ogawa, T. Nishimur, T. Hatanaka, S. Kakizaki, N. Shimada, K. Kawata, T. Tanaka, H. Ohama, K. Nouso, A. Morishita, A. Tsutsui, T. Nagano, N. Itokawa, T. Okubo, T. Arai, M. Imai, A. Naganuma, Y. Koizumi, S. Nakamura, K. Joko, H. Iijima, Y. Hiasa, F. Pedica, F. De Cobelli, F. Ratti, L. Aldrighetti, M. Kudo, S. Cascinu & A. Casadei-Gardini. (2022) Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open 7:6, pages 100591.
Crossref
V. V. Breder, I. A. Pokataev, Omar Ahmed Yousri Mohamed Zak Abdelgafur, I. V. Avramenko, A. Yu. Goryainova & N. M. Kiselyov. (2022) Hepatocellular cancer of non-viral etiology: more questions than answers?. Medical alphabet:26, pages 7-12.
Crossref
Jan Stępniak, Joanna Krawczyk-Lipiec, Andrzej Lewiński & Małgorzata Karbownik-Lewińska. (2022) Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid. Biomedicines 10:11, pages 2890.
Crossref
Paolo Giuffrida, Ciro Celsa, Michela Antonucci, Marta Peri, Maria Vittoria Grassini, Gabriele Rancatore, Carmelo Marco Giacchetto, Roberto Cannella, Lorena Incorvaia, Lidia Rita Corsini, Piera Morana, Claudia La Mantia, Giuseppe Badalamenti, Giuseppe Brancatelli, Calogero Cammà & Giuseppe Cabibbo. (2022) The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints. Biomedicines 10:11, pages 2827.
Crossref
Fabio Piscaglia & Federico Ravaioli. (2022) Gaining knowledge for the choice and use of systemic therapies in the treatment of hepatocellular carcinoma also requires real life and investigators conducted observational studies. Digestive and Liver Disease 54:11, pages 1561-1562.
Crossref
Domenica Lorusso, Romano Danesi, Laura Deborah Locati, Gianluca Masi, Ugo De Giorgi, Angiolo Gadducci, Sandro Pignata, Roberto Sabbatini, Antonella Savarese, Giorgio Valabrega, Claudio Zamagni & Nicoletta Colombo. (2022) Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. Frontiers in Oncology 12.
Crossref
Yoshihiko Yano, Atsushi Yamamoto, Akihiro Minami, Kenji Momose, Takuya Mimura, Soo Ki Kim, Hiroki Hayashi, Takuo Kado, Hirotaka Hirano, Seiya Hirohata, Seitetsu Yoon, Katsuhisa Nishi, Hiroshi Tei, Hidenori Tanaka, Sachiko Oouchi, Takanori Matsuura, Eiichiro Yasutomi, Yuri Hatazawa, Yuuki Shiomi, Yoshihide Ueda & Yuzo Kodama. (2022) Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma. JGH Open 6:6, pages 427-433.
Crossref
Shou-Wu Lee, Sheng-Shun Yang, Han-Chung Lien, Yen-Chun Peng, Chung-Wang Ko & Teng-Yu Lee. (2022) Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population. Journal of Clinical Medicine 11:5, pages 1444.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.